Cargando…
Taste, A New Incentive to Switch to (R)-Praziquantel in Schistosomiasis Treatment
BACKGROUND: Praziquantel (PZQ) is the drug compound of choice in the control and treatment of schistosomiasis. PZQ is administered as a racemate, i. e. 1∶1 mixture of enantiomers. The schistosomicidal activity arises from one PZQ-enantiomer, whereas the other enantiomer does not contribute to the ac...
Autores principales: | Meyer, Thorsten, Sekljic, Harald, Fuchs, Stefan, Bothe, Heiko, Schollmeyer, Dieter, Miculka, Christian |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614124/ https://www.ncbi.nlm.nih.gov/pubmed/19159015 http://dx.doi.org/10.1371/journal.pntd.0000357 |
Ejemplares similares
-
Praziquantel for the treatment of schistosomiasis during human pregnancy
por: Friedman, Jennifer F, et al.
Publicado: (2018) -
Anaphylactic reaction to praziquantel following schistosomiasis treatment
por: Vasconcelos, Géssica Almeida, et al.
Publicado: (2023) -
Praziquantel Could Be the Appropriate Choice for the Diagnostic Treatment of Schistosomiasis
por: Fukuchi, Takahiko, et al.
Publicado: (2019) -
Oxamniquine derivatives overcome Praziquantel treatment limitations for Schistosomiasis
por: Alwan, Sevan N., et al.
Publicado: (2023) -
Human Schistosomiasis Resistance to Praziquantel in China: Should We Be Worried?
por: Seto, Edmund Y. W., et al.
Publicado: (2011)